UnitedHealth Group
UNH
$390.11
+1.37%
UnitedHealth Group is a diversified healthcare company operating through two primary platforms: UnitedHealthcare, which provides health insurance coverage to approximately 51 million members globally, and Optum, which offers healthcare services including pharmacy benefit management, outpatient care, and data analytics. As one of the largest private health insurers in the United States, UnitedHealth holds a dominant market position, leveraging its integrated model to drive scale and efficiency across the healthcare value chain. The current investor narrative centers on the company's operational recovery following a challenging 2025, with recent quarterly results showing improved earnings and revenue growth, while an ongoing Department of Justice investigation into its Medicare billing practices continues to create regulatory overhang. The stock has rallied sharply off its 52-week low, reflecting optimism about Medicare reimbursement rates and the company's ability to navigate a complex policy environment.…
UNH
UnitedHealth Group
$390.11
Related headlines
Investment Opinion: Should I buy UNH Today?
Based on the analysis, UNH is rated a Buy. The thesis is that UnitedHealth's operational recovery, dominant market position, and attractive forward valuation provide a favorable risk-reward, despite regulatory overhang. The consensus analyst rating is 'Buy' with an average target price of $475.23, implying 18.3% upside from the current price of $401.73.
Sign up to view all
UNH 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The company's operational recovery is evident in the Q1 2026 results, and the forward valuation is reasonable. However, the unresolved DOJ investigation and modest revenue growth temper confidence. If the investigation is resolved favorably and earnings continue to improve, the stock could outperform. Conversely, any negative development could lead to a downgrade. The key factors to monitor are regulatory news, quarterly earnings, and margin trends.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +21.8% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+21.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
UnitedHealth is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.59 (where 1 is Strong Buy and 5 is Sell). The average target price is $475.23, implying an upside of +18.3% from the current price of $401.73. The target price range is wide, from a low of $313.00 to a high of $529.00, indicating significant uncertainty about the company's future performance. The high target assumes continued operational recovery and potential multiple expansion, while the low target reflects concerns about regulatory actions and competitive pressures.
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a compelling bull case driven by a strong operational recovery, attractive forward valuation, and dominant market position. The stock has rallied 48% over the past year, reflecting improving fundamentals and analyst optimism. However, the bear case highlights significant regulatory risks, modest revenue growth, and a valuation that is not cheap on trailing earnings. The most important tension is the resolution of the DOJ investigation: a favorable outcome could unlock further upside, while an adverse ruling could severely impact earnings and sentiment. Currently, the bull case has stronger evidence, given the robust Q1 2026 results and analyst consensus, but the regulatory overhang remains a critical wildcard.
Bullish
- Strong Operational Recovery: Q1 2026 EPS of $6.90 significantly exceeded the depressed Q4 2025 EPS of $0.011, demonstrating a sharp rebound in profitability. Revenue grew 1.96% YoY to $111.72 billion, with operating margin recovering to 8.05% from 0.34% in Q4 2025.
- Attractive Forward Valuation: The forward PE of 17.91x is well below the trailing PE of 24.95x, implying the market expects substantial earnings growth. This is supported by analyst consensus EPS estimates of $34.29 for the next fiscal year, which would represent a significant increase from current levels.
- Dominant Market Position: UnitedHealth serves approximately 51 million members globally, making it one of the largest health insurers. Its integrated model with Optum provides a competitive advantage in managing healthcare costs and improving outcomes, as evidenced by its 18.5% gross margin and 2.7% net margin.
- Analyst Consensus Buy: With a consensus rating of 'Buy' and a mean recommendation score of 1.59 (1=Strong Buy, 5=Sell), analysts are overwhelmingly positive. The average price target of $475.23 implies an upside of +18.3% from the current price of $401.73.
Bearish
- Regulatory Overhang from DOJ Investigation: The ongoing Department of Justice investigation into Medicare billing practices creates significant legal and financial uncertainty. A negative outcome could result in substantial fines, changes to billing practices, and reputational damage, which is not fully reflected in current valuation.
- Elevated Valuation Relative to History: The trailing PE of 24.95x is above the 5-year average of around 20x, suggesting the stock is trading at a premium. The PEG ratio of -1.62 is negative, indicating that the market expects earnings to decline or that growth is not sustainable, which could lead to multiple compression.
- Modest Revenue Growth: Revenue growth of only 1.96% YoY in Q1 2026 is sluggish for a company trading at a premium valuation. This reflects the mature nature of the health insurance industry and intense competition, limiting the potential for rapid top-line expansion.
- Thin Net Margins: The net margin of 2.69% is razor-thin, leaving little room for error. Any unexpected increase in medical costs or regulatory changes could significantly impact profitability, as seen in Q4 2025 when net income nearly vanished.
UNH Technical Analysis
UnitedHealth's stock is in a strong uptrend, with a 1-year price change of +47.97% and a 6-month change of +37.02%. The current price of $401.73 sits at 87% of the 52-week range (low of $255.97, high of $461.62), indicating the stock is trading near its highs, which suggests robust momentum but also potential overextension. The stock has recovered significantly from its 52-week low, and the sustained upward trajectory reflects improving fundamentals and investor confidence.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$256-$462
Price range past year
Annual Return
+28.6%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -9.6% | +2.5% |
| 3m | +0.4% | +2.7% |
| 6m | +34.5% | +11.1% |
| 1y | +28.6% | +20.5% |
| ytd | +16.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
UnitedHealth's revenue growth has been modest but positive, with Q1 2026 revenue of $111.72 billion, up 1.96% year-over-year. This growth is driven primarily by the UnitedHealthcare segment, which contributed $82.99 billion in revenue, while OptumHealth added $4.58 billion. The company's revenue trajectory has been relatively stable, with quarterly revenues ranging from $100.8 billion to $113.2 billion over the past two years, indicating a mature but resilient business. The modest growth rate reflects the scale of the company and the competitive pressures in the health insurance industry.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Given UnitedHealth's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 24.95x, while the forward PE is 17.91x, implying that the market expects significant earnings growth. The gap between trailing and forward PE suggests that the market is pricing in a recovery in earnings, which is consistent with the company's recent operational improvements. The PEG ratio is negative at -1.62, which is unusual and may indicate that the market expects earnings to decline or that the growth rate is not sustainable.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. UnitedHealth's net margin is razor-thin at 2.69%, leaving little buffer for cost overruns or pricing pressure. The company carries a debt-to-equity ratio of 0.83, which is manageable but not insignificant, and interest expenses of $955 million in Q1 2026 weigh on earnings. Revenue growth is modest at 1.96% YoY, indicating a mature business with limited top-line expansion. The Q4 2025 earnings collapse (EPS of $0.011) highlights the potential for significant earnings volatility, driven by factors such as medical cost trends and regulatory changes.